Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID. We co...
Saved in:
| Published in: | The Lancet infectious diseases Vol. 23; no. 10; pp. 1119 - 1129 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Ltd
01-10-2023
Elsevier Limited |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.
We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30–85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov, NCT04510194.
Between Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56·1%) of 1126 participants were female and 494 (43·9%) were male; 44 (7·0%) of 632 women were pregnant. The median age was 45 years (IQR 37–54) and median BMI was 29·8 kg/m2 (IQR 27·0–34·2). Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2–8·2) in participants who received metformin and 10·4% (7·8–12·9) in those who received identical metformin placebo (hazard ratio [HR] 0·59, 95% CI 0·39–0·89; p=0·012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15–0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo.
Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe.
Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences. |
|---|---|
| AbstractList | Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.
We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30-85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov, NCT04510194.
Between Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56·1%) of 1126 participants were female and 494 (43·9%) were male; 44 (7·0%) of 632 women were pregnant. The median age was 45 years (IQR 37-54) and median BMI was 29·8 kg/m
(IQR 27·0-34·2). Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2-8·2) in participants who received metformin and 10·4% (7·8-12·9) in those who received identical metformin placebo (hazard ratio [HR] 0·59, 95% CI 0·39-0·89; p=0·012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15-0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59-1·64) or fluvoxamine (1·36, 0·78-2·34) compared with placebo.
Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe.
Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences. Summary Background Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID. Methods We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30–85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov, NCT04510194. Findings Between Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56·1%) of 1126 participants were female and 494 (43·9%) were male; 44 (7·0%) of 632 women were pregnant. The median age was 45 years (IQR 37–54) and median BMI was 29·8 kg/m2 (IQR 27·0–34·2). Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2–8·2) in participants who received metformin and 10·4% (7·8–12·9) in those who received identical metformin placebo (hazard ratio [HR] 0·59, 95% CI 0·39–0·89; p=0·012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15–0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo. Interpretation Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe. Funding Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences. Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID. We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30–85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov, NCT04510194. Between Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56·1%) of 1126 participants were female and 494 (43·9%) were male; 44 (7·0%) of 632 women were pregnant. The median age was 45 years (IQR 37–54) and median BMI was 29·8 kg/m2 (IQR 27·0–34·2). Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2–8·2) in participants who received metformin and 10·4% (7·8–12·9) in those who received identical metformin placebo (hazard ratio [HR] 0·59, 95% CI 0·39–0·89; p=0·012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15–0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo. Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe. Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences. Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.BACKGROUNDPost-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID.We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30-85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov, NCT04510194.METHODSWe conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30-85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov, NCT04510194.Between Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56·1%) of 1126 participants were female and 494 (43·9%) were male; 44 (7·0%) of 632 women were pregnant. The median age was 45 years (IQR 37-54) and median BMI was 29·8 kg/m2 (IQR 27·0-34·2). Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2-8·2) in participants who received metformin and 10·4% (7·8-12·9) in those who received identical metformin placebo (hazard ratio [HR] 0·59, 95% CI 0·39-0·89; p=0·012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15-0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59-1·64) or fluvoxamine (1·36, 0·78-2·34) compared with placebo.FINDINGSBetween Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56·1%) of 1126 participants were female and 494 (43·9%) were male; 44 (7·0%) of 632 women were pregnant. The median age was 45 years (IQR 37-54) and median BMI was 29·8 kg/m2 (IQR 27·0-34·2). Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2-8·2) in participants who received metformin and 10·4% (7·8-12·9) in those who received identical metformin placebo (hazard ratio [HR] 0·59, 95% CI 0·39-0·89; p=0·012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15-0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59-1·64) or fluvoxamine (1·36, 0·78-2·34) compared with placebo.Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe.INTERPRETATIONOutpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe.Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences.FUNDINGParsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences. |
| Author | Wirtz, Esteban Lemus Campora, Paula Singh, Palak Hartman, Katrina M Christensen, Grace Zinkl, Lena Mehta, Tanvi Challa, Anup Parrens, Elliott Ingraham, Nicholas E Parra, Daniela Thompson, Jennifer L Charles, Jill Brea, Jannis Simmons, Lucas Lee, Samuel Lindberg, Sarah Murray, Thomas A Fenno, Sarah L Anderson, Blake Fairbairn, Faith M Deng, Nikita Dunn, Alex T Jeng, Arthur C Thompson, Jennifer Nicklas, Jacinda M Stauffer, Maxwell T Rypka, Katelyn J Lindberg, Sarah M Sherwood, Nancy E Seloadji, Paula Ngonyama, Rumbidzai Reddy, Naveen Sherwood, Nancy Rao, Via Tordsen, Walker J Watson, Ray HB Cohen, Ken Huling, Jared D Connelly, Bo Reddy, Neha V Siegart, Jamie L Belani, Hrishikesh K Boulware, David R Liebovitz, David M Tignanelli, Christopher J Saveraid, Hanna G Sinelli, Isabella Mohamud, Zeinab Johnson, Darrell M LaBar, Derek D Patel, Barkha Beckman, Kenneth B Siegel, Lianne K Zolik, Madeline R Hagen, Aubrey A Karger, Amy B Pullen, Matthew Klatt, Nichole R Tople, Tannon L Kuehl, Erik A Buse, John B Griffiths, Gwendolyn Beckman, Kenny B Machicado, Rosa |
| Author_xml | – sequence: 1 givenname: Carolyn T surname: Bramante fullname: Bramante, Carolyn T email: bramante@umn.edu organization: Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA – sequence: 2 givenname: John B surname: Buse fullname: Buse, John B organization: Endocrinology, University of North Carolina, Chapel Hill, NC, USA – sequence: 3 givenname: David M surname: Liebovitz fullname: Liebovitz, David M organization: General Internal Medicine, Northwestern University, Chicago, IL, USA – sequence: 4 givenname: Jacinda M surname: Nicklas fullname: Nicklas, Jacinda M organization: General Internal Medicine, University of Colorado, Denver, CO, USA – sequence: 5 givenname: Michael A surname: Puskarich fullname: Puskarich, Michael A organization: Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA – sequence: 6 givenname: Ken surname: Cohen fullname: Cohen, Ken organization: UnitedHealth Group, Optum Labs, Minnetonka, MN, USA – sequence: 7 givenname: Hrishikesh K surname: Belani fullname: Belani, Hrishikesh K organization: Department of Medicine, Olive View, University of California, Los Angeles, CA, USA – sequence: 8 givenname: Blake J surname: Anderson fullname: Anderson, Blake J organization: Atlanta Veterans Affairs Medical Center, Atlanta, GA, USA – sequence: 10 givenname: Christopher J surname: Tignanelli fullname: Tignanelli, Christopher J organization: Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN, USA – sequence: 11 givenname: Jennifer L surname: Thompson fullname: Thompson, Jennifer L organization: Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, USA – sequence: 12 givenname: Matthew surname: Pullen fullname: Pullen, Matthew organization: Division of Infectious Diseases and International Medicine, Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA – sequence: 13 givenname: Esteban Lemus surname: Wirtz fullname: Wirtz, Esteban Lemus organization: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA – sequence: 14 givenname: Lianne K surname: Siegel fullname: Siegel, Lianne K organization: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA – sequence: 15 givenname: Jennifer L surname: Proper fullname: Proper, Jennifer L organization: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA – sequence: 16 givenname: David J surname: Odde fullname: Odde, David J organization: Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN, USA – sequence: 17 givenname: Nichole R surname: Klatt fullname: Klatt, Nichole R organization: Department of Surgery, Medical School, University of Minnesota, Minneapolis, MN, USA – sequence: 19 givenname: Sarah M surname: Lindberg fullname: Lindberg, Sarah M organization: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA – sequence: 20 givenname: Amy B surname: Karger fullname: Karger, Amy B organization: Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, MN, USA – sequence: 22 givenname: Spencer M surname: Erickson fullname: Erickson, Spencer M organization: Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA – sequence: 23 givenname: Sarah L surname: Fenno fullname: Fenno, Sarah L organization: Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA – sequence: 24 givenname: Katrina M surname: Hartman fullname: Hartman, Katrina M organization: Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA – sequence: 25 givenname: Michael R surname: Rose fullname: Rose, Michael R organization: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 26 givenname: Tanvi surname: Mehta fullname: Mehta, Tanvi organization: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA – sequence: 27 givenname: Barkha surname: Patel fullname: Patel, Barkha organization: Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA – sequence: 28 givenname: Gwendolyn surname: Griffiths fullname: Griffiths, Gwendolyn organization: Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA – sequence: 29 givenname: Neeta S surname: Bhat fullname: Bhat, Neeta S organization: Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, USA – sequence: 30 givenname: Thomas A surname: Murray fullname: Murray, Thomas A organization: Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA – sequence: 31 givenname: David R surname: Boulware fullname: Boulware, David R organization: Division of Infectious Diseases and International Medicine, Department of Medicine, Medical School, University of Minnesota, Minneapolis, MN, USA – sequence: 32 givenname: Blake surname: Anderson fullname: Anderson, Blake – sequence: 33 givenname: Riannon C surname: Atwater fullname: Atwater, Riannon C – sequence: 34 givenname: Nandini surname: Avula fullname: Avula, Nandini – sequence: 35 givenname: Kenny B surname: Beckman fullname: Beckman, Kenny B – sequence: 36 givenname: Hrishikesh K surname: Belani fullname: Belani, Hrishikesh K – sequence: 37 givenname: David R surname: Boulware fullname: Boulware, David R – sequence: 38 givenname: Carolyn T surname: Bramante fullname: Bramante, Carolyn T – sequence: 39 givenname: Jannis surname: Brea fullname: Brea, Jannis – sequence: 40 givenname: Courtney A surname: Broedlow fullname: Broedlow, Courtney A – sequence: 41 givenname: John B surname: Buse fullname: Buse, John B – sequence: 42 givenname: Paula surname: Campora fullname: Campora, Paula – sequence: 43 givenname: Anup surname: Challa fullname: Challa, Anup – sequence: 44 givenname: Jill surname: Charles fullname: Charles, Jill – sequence: 45 givenname: Grace surname: Christensen fullname: Christensen, Grace – sequence: 46 givenname: Theresa surname: Christiansen fullname: Christiansen, Theresa – sequence: 47 givenname: Ken surname: Cohen fullname: Cohen, Ken – sequence: 48 givenname: Bo surname: Connelly fullname: Connelly, Bo – sequence: 49 givenname: Srijani surname: Datta fullname: Datta, Srijani – sequence: 50 givenname: Nikita surname: Deng fullname: Deng, Nikita – sequence: 51 givenname: Alex T surname: Dunn fullname: Dunn, Alex T – sequence: 52 givenname: Spencer M surname: Erickson fullname: Erickson, Spencer M – sequence: 53 givenname: Faith M surname: Fairbairn fullname: Fairbairn, Faith M – sequence: 54 givenname: Sarah L surname: Fenno fullname: Fenno, Sarah L – sequence: 55 givenname: Daniel J surname: Fraser fullname: Fraser, Daniel J – sequence: 56 givenname: Regina D surname: Fricton fullname: Fricton, Regina D – sequence: 57 givenname: Gwen surname: Griffiths fullname: Griffiths, Gwen – sequence: 58 givenname: Aubrey A surname: Hagen fullname: Hagen, Aubrey A – sequence: 59 givenname: Katrina M surname: Hartman fullname: Hartman, Katrina M – sequence: 60 givenname: Audrey F surname: Hendrickson fullname: Hendrickson, Audrey F – sequence: 61 givenname: Jared D surname: Huling fullname: Huling, Jared D – sequence: 62 givenname: Nicholas E surname: Ingraham fullname: Ingraham, Nicholas E – sequence: 63 givenname: Arthur C surname: Jeng fullname: Jeng, Arthur C – sequence: 64 givenname: Darrell M surname: Johnson fullname: Johnson, Darrell M – sequence: 65 givenname: Amy B surname: Karger fullname: Karger, Amy B – sequence: 66 givenname: Nichole R surname: Klatt fullname: Klatt, Nichole R – sequence: 68 givenname: Derek D surname: LaBar fullname: LaBar, Derek D – sequence: 69 givenname: Samuel surname: Lee fullname: Lee, Samuel – sequence: 70 givenname: David M surname: Liebovitz fullname: Liebovitz, David M – sequence: 71 givenname: Sarah surname: Lindberg fullname: Lindberg, Sarah – sequence: 72 givenname: Darlette G surname: Luke fullname: Luke, Darlette G – sequence: 73 givenname: Rosario surname: Machicado fullname: Machicado, Rosario – sequence: 74 givenname: Zeinab surname: Mohamud fullname: Mohamud, Zeinab – sequence: 75 givenname: Thomas A surname: Murray fullname: Murray, Thomas A – sequence: 76 givenname: Rumbidzai surname: Ngonyama fullname: Ngonyama, Rumbidzai – sequence: 77 givenname: Jacinda M surname: Nicklas fullname: Nicklas, Jacinda M – sequence: 78 givenname: David J surname: Odde fullname: Odde, David J – sequence: 79 givenname: Elliott surname: Parrens fullname: Parrens, Elliott – sequence: 80 givenname: Daniela surname: Parra fullname: Parra, Daniela – sequence: 81 givenname: Barkha surname: Patel fullname: Patel, Barkha – sequence: 82 givenname: Jennifer L surname: Proper fullname: Proper, Jennifer L – sequence: 83 givenname: Matthew F surname: Pullen fullname: Pullen, Matthew F – sequence: 84 givenname: Michael A surname: Puskarich fullname: Puskarich, Michael A – sequence: 85 givenname: Via surname: Rao fullname: Rao, Via – sequence: 86 givenname: Neha V surname: Reddy fullname: Reddy, Neha V – sequence: 87 givenname: Naveen surname: Reddy fullname: Reddy, Naveen – sequence: 88 givenname: Katelyn J surname: Rypka fullname: Rypka, Katelyn J – sequence: 89 givenname: Hanna G surname: Saveraid fullname: Saveraid, Hanna G – sequence: 90 givenname: Paula surname: Seloadji fullname: Seloadji, Paula – sequence: 91 givenname: Arman surname: Shahriar fullname: Shahriar, Arman – sequence: 92 givenname: Nancy surname: Sherwood fullname: Sherwood, Nancy – sequence: 93 givenname: Jamie L surname: Siegart fullname: Siegart, Jamie L – sequence: 94 givenname: Lianne K surname: Siegel fullname: Siegel, Lianne K – sequence: 95 givenname: Lucas surname: Simmons fullname: Simmons, Lucas – sequence: 96 givenname: Isabella surname: Sinelli fullname: Sinelli, Isabella – sequence: 98 givenname: Andrew surname: Snyder fullname: Snyder, Andrew – sequence: 99 givenname: Maxwell T surname: Stauffer fullname: Stauffer, Maxwell T – sequence: 101 givenname: Christopher J surname: Tignanelli fullname: Tignanelli, Christopher J – sequence: 104 givenname: Ray HB surname: Watson fullname: Watson, Ray HB – sequence: 105 givenname: Beiqing surname: Wu fullname: Wu, Beiqing – sequence: 106 givenname: Adnin surname: Zaman fullname: Zaman, Adnin – sequence: 107 givenname: Madeline R surname: Zolik fullname: Zolik, Madeline R – sequence: 108 givenname: Lena surname: Zinkl fullname: Zinkl, Lena |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37302406$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc1uEzEUhS1URNvAI4AssUmlDvh3HHeDUPirVCkLWraWM75DXc3YU9tTiafiFXGS0gUbVr6-9_O5Rz6n6CjEAAi9puQdJbR9_50KxRtOtF4yfkYI07phz9BJbYtGCKmO9vUBOUanOd8RQhUl4gU65ooTJkh7gn5v5jLZ4iEUXBLYMu6q2OP15sflp4ZqbIPDPnTeQehgN5liLs3TuIvB-eJjwPEBEqYEjzGU24yXB2Rzc312gS0e56H4roonOMepisbRZ3Dn-H62Ls3TAM128KE2JpvsMMDQ_Exxnur91mbAvNrzdniJnvd2yPDq8Vygmy-fr9ffmqvN18v1x6umE4KUhhHBWs54L4Rtt2DbvgXVtZRqLaUGSVbEOkHkiiulpbAWgK8srLRzrgdF-AItD7pTivcz5GKq3Q6GwQaIczZsxSSVmilV0bf_oHdxTqG6q1SrZd2qZKXkgepSzDlBb6bkR5t-GUrMLlGzT9Ts4jKMm32itVigN4_q83YE9_Tqb4QV-HAAoH7Hg4dkcud3WTmfoCvGRf-fFX8AqqGv-w |
| CitedBy_id | crossref_primary_10_3390_jcdd10120478 crossref_primary_10_1152_physrev_00032_2023 crossref_primary_10_1128_mbio_01489_23 crossref_primary_10_1093_cid_ciae159 crossref_primary_10_3389_fimmu_2023_1275001 crossref_primary_10_1093_cid_ciae154 crossref_primary_10_1016_S1473_3099_23_00557_1 crossref_primary_10_3390_immuno4020010 crossref_primary_10_5812_ijem_139768 crossref_primary_10_1210_endrev_bnad032 crossref_primary_10_1093_infdis_jiad286 crossref_primary_10_1016_j_jinf_2024_106130 crossref_primary_10_1016_j_gloepi_2024_100142 crossref_primary_10_1093_jac_dkad275 crossref_primary_10_2147_CLEP_S458901 crossref_primary_10_3390_ijms242317039 crossref_primary_10_1016_j_amjmed_2024_02_010 crossref_primary_10_5692_clinicalneurol_cn_001902 crossref_primary_10_1093_eurjpc_zwae070 crossref_primary_10_25259_AJPPS_2023_012 crossref_primary_10_1016_j_jns_2023_122812 crossref_primary_10_1017_cts_2023_668 crossref_primary_10_1016_j_arbres_2024_02_003 crossref_primary_10_1093_ofid_ofad466 crossref_primary_10_1126_science_adl0867 crossref_primary_10_3390_ijms242417147 crossref_primary_10_3390_ijerph21030325 crossref_primary_10_1007_s10787_023_01383_x crossref_primary_10_3390_diagnostics14070711 crossref_primary_10_1016_j_arr_2024_102400 crossref_primary_10_1016_j_jiac_2024_02_009 crossref_primary_10_1128_cmr_00119_23 crossref_primary_10_1016_j_jiph_2023_06_017 crossref_primary_10_1093_cid_ciad648 crossref_primary_10_3390_jcm13071874 crossref_primary_10_1038_s41390_023_02878_7 crossref_primary_10_1186_s10020_024_00855_2 crossref_primary_10_1093_braincomms_fcae080 crossref_primary_10_1093_cvr_cvae090 crossref_primary_10_1111_resp_14596 crossref_primary_10_1093_cid_ciad685 crossref_primary_10_58647_DRUGREPO_24_1_0007 crossref_primary_10_1016_j_redox_2023_102957 crossref_primary_10_1080_14712598_2023_2296569 crossref_primary_10_1016_j_immuni_2024_05_010 crossref_primary_10_3390_ijms241612962 crossref_primary_10_1111_dom_15663 crossref_primary_10_1016_S1473_3099_23_00355_9 crossref_primary_10_3390_v16071060 crossref_primary_10_1186_s12933_023_02097_8 crossref_primary_10_3390_toxics11100875 crossref_primary_10_1038_s41579_023_01001_1 crossref_primary_10_1093_ofid_ofad686 crossref_primary_10_3390_biomedicines12061223 crossref_primary_10_3390_microorganisms12020383 crossref_primary_10_1002_jmv_29343 crossref_primary_10_1186_s12913_024_11071_3 crossref_primary_10_12688_wellcomeopenres_19455_2 crossref_primary_10_1097_JOM_0000000000003059 crossref_primary_10_3390_ijms25105190 crossref_primary_10_1007_s10534_024_00590_5 crossref_primary_10_1016_j_mehy_2023_111186 crossref_primary_10_1016_j_jacadv_2024_100961 crossref_primary_10_3390_v16040651 crossref_primary_10_3389_fmicb_2024_1396031 crossref_primary_10_1136_bmj_p1306 crossref_primary_10_3389_fimmu_2023_1257192 crossref_primary_10_3390_microorganisms11082073 |
| Cites_doi | 10.1016/S2213-2600(22)00217-X 10.1016/S2213-2600(21)00377-5 10.1002/jmv.26728 10.1016/j.eclinm.2021.101019 10.1016/S0140-6736(22)02467-9 10.1016/S2214-109X(21)00448-4 10.1016/S1470-2045(19)30854-X 10.1016/j.biopha.2022.113223 10.1056/NEJMoa2201662 10.1172/jci.insight.148003 10.1016/j.ajogmf.2022.100700 10.1002/uog.19084 10.1111/dom.14313 10.1016/S1473-3099(21)00703-9 10.1002/14651858.CD002967.pub3 10.1038/s41418-021-00916-7 10.1016/j.cct.2015.06.008 10.1001/jamahealthforum.2022.1809 10.3892/etm.2021.10010 10.1001/jamasurg.2020.0416 10.1056/NEJMoa1811403 10.1038/s41586-020-2286-9 10.1056/NEJMoa1809944 10.1016/j.cct.2021.106656 10.1016/S2589-7500(22)00048-6 10.1056/NEJMclde2204691 10.1177/1740774520941419 10.1056/NEJMra1510064 10.1089/chi.2018.0043 10.1161/CIRCHEARTFAILURE.112.000162 10.1186/1472-6947-12-127 |
| ContentType | Journal Article |
| Contributor | Campora, Paula Singh, Palak Hartman, Katrina M Christensen, Grace Zinkl, Lena Challa, Anup Parrens, Elliott Ingraham, Nicholas E Parra, Daniela Charles, Jill Brea, Jannis Simmons, Lucas Watson, Ray Hb Lee, Samuel Lindberg, Sarah Murray, Thomas A Anderson, Blake Fairbairn, Faith M Fenno, Sarah L Deng, Nikita Dunn, Alex T Jeng, Arthur C Thompson, Jennifer Nicklas, Jacinda M Stauffer, Maxwell T Rypka, Katelyn J Seloadji, Paula Ngonyama, Rumbidzai Reddy, Naveen Sherwood, Nancy Rao, Via Tordsen, Walker J Cohen, Ken Huling, Jared D Connelly, Bo Reddy, Neha V Siegart, Jamie L Belani, Hrishikesh K Boulware, David R Liebovitz, David M Saveraid, Hanna G Tignanelli, Christopher J Sinelli, Isabella Mohamud, Zeinab Johnson, Darrell M LaBar, Derek D Patel, Barkha Siegel, Lianne K Zolik, Madeline R Hagen, Aubrey A Karger, Amy B Klatt, Nichole R Tople, Tannon L Kuehl, Erik A Buse, John B Beckman, Kenny B Machicado, Rosario Shahriar, Arman Proper, Jennifer L Puskarich, Michael A Christiansen, Theresa Erickson, Spencer M Griffiths, Gwen Wu, Beiqing Zaman, Adnin Atwat |
| Contributor_xml | – sequence: 1 givenname: Blake surname: Anderson fullname: Anderson, Blake – sequence: 2 givenname: Riannon C surname: Atwater fullname: Atwater, Riannon C – sequence: 3 givenname: Nandini surname: Avula fullname: Avula, Nandini – sequence: 4 givenname: Kenny B surname: Beckman fullname: Beckman, Kenny B – sequence: 5 givenname: Hrishikesh K surname: Belani fullname: Belani, Hrishikesh K – sequence: 6 givenname: David R surname: Boulware fullname: Boulware, David R – sequence: 7 givenname: Carolyn T surname: Bramante fullname: Bramante, Carolyn T – sequence: 8 givenname: Jannis surname: Brea fullname: Brea, Jannis – sequence: 9 givenname: Courtney A surname: Broedlow fullname: Broedlow, Courtney A – sequence: 10 givenname: John B surname: Buse fullname: Buse, John B – sequence: 11 givenname: Paula surname: Campora fullname: Campora, Paula – sequence: 12 givenname: Anup surname: Challa fullname: Challa, Anup – sequence: 13 givenname: Jill surname: Charles fullname: Charles, Jill – sequence: 14 givenname: Grace surname: Christensen fullname: Christensen, Grace – sequence: 15 givenname: Theresa surname: Christiansen fullname: Christiansen, Theresa – sequence: 16 givenname: Ken surname: Cohen fullname: Cohen, Ken – sequence: 17 givenname: Bo surname: Connelly fullname: Connelly, Bo – sequence: 18 givenname: Srijani surname: Datta fullname: Datta, Srijani – sequence: 19 givenname: Nikita surname: Deng fullname: Deng, Nikita – sequence: 20 givenname: Alex T surname: Dunn fullname: Dunn, Alex T – sequence: 21 givenname: Spencer M surname: Erickson fullname: Erickson, Spencer M – sequence: 22 givenname: Faith M surname: Fairbairn fullname: Fairbairn, Faith M – sequence: 23 givenname: Sarah L surname: Fenno fullname: Fenno, Sarah L – sequence: 24 givenname: Daniel J surname: Fraser fullname: Fraser, Daniel J – sequence: 25 givenname: Regina D surname: Fricton fullname: Fricton, Regina D – sequence: 26 givenname: Gwen surname: Griffiths fullname: Griffiths, Gwen – sequence: 27 givenname: Aubrey A surname: Hagen fullname: Hagen, Aubrey A – sequence: 28 givenname: Katrina M surname: Hartman fullname: Hartman, Katrina M – sequence: 29 givenname: Audrey F surname: Hendrickson fullname: Hendrickson, Audrey F – sequence: 30 givenname: Jared D surname: Huling fullname: Huling, Jared D – sequence: 31 givenname: Nicholas E surname: Ingraham fullname: Ingraham, Nicholas E – sequence: 32 givenname: Arthur C surname: Jeng fullname: Jeng, Arthur C – sequence: 33 givenname: Darrell M surname: Johnson fullname: Johnson, Darrell M – sequence: 34 givenname: Amy B surname: Karger fullname: Karger, Amy B – sequence: 35 givenname: Nichole R surname: Klatt fullname: Klatt, Nichole R – sequence: 36 givenname: Erik A surname: Kuehl fullname: Kuehl, Erik A – sequence: 37 givenname: Derek D surname: LaBar fullname: LaBar, Derek D – sequence: 38 givenname: Samuel surname: Lee fullname: Lee, Samuel – sequence: 39 givenname: David M surname: Liebovitz fullname: Liebovitz, David M – sequence: 40 givenname: Sarah surname: Lindberg fullname: Lindberg, Sarah – sequence: 41 givenname: Darlette G surname: Luke fullname: Luke, Darlette G – sequence: 42 givenname: Rosario surname: Machicado fullname: Machicado, Rosario – sequence: 43 givenname: Zeinab surname: Mohamud fullname: Mohamud, Zeinab – sequence: 44 givenname: Thomas A surname: Murray fullname: Murray, Thomas A – sequence: 45 givenname: Rumbidzai surname: Ngonyama fullname: Ngonyama, Rumbidzai – sequence: 46 givenname: Jacinda M surname: Nicklas fullname: Nicklas, Jacinda M – sequence: 47 givenname: David J surname: Odde fullname: Odde, David J – sequence: 48 givenname: Elliott surname: Parrens fullname: Parrens, Elliott – sequence: 49 givenname: Daniela surname: Parra fullname: Parra, Daniela – sequence: 50 givenname: Barkha surname: Patel fullname: Patel, Barkha – sequence: 51 givenname: Jennifer L surname: Proper fullname: Proper, Jennifer L – sequence: 52 givenname: Matthew F surname: Pullen fullname: Pullen, Matthew F – sequence: 53 givenname: Michael A surname: Puskarich fullname: Puskarich, Michael A – sequence: 54 givenname: Via surname: Rao fullname: Rao, Via – sequence: 55 givenname: Neha V surname: Reddy fullname: Reddy, Neha V – sequence: 56 givenname: Naveen surname: Reddy fullname: Reddy, Naveen – sequence: 57 givenname: Katelyn J surname: Rypka fullname: Rypka, Katelyn J – sequence: 58 givenname: Hanna G surname: Saveraid fullname: Saveraid, Hanna G – sequence: 59 givenname: Paula surname: Seloadji fullname: Seloadji, Paula – sequence: 60 givenname: Arman surname: Shahriar fullname: Shahriar, Arman – sequence: 61 givenname: Nancy surname: Sherwood fullname: Sherwood, Nancy – sequence: 62 givenname: Jamie L surname: Siegart fullname: Siegart, Jamie L – sequence: 63 givenname: Lianne K surname: Siegel fullname: Siegel, Lianne K – sequence: 64 givenname: Lucas surname: Simmons fullname: Simmons, Lucas – sequence: 65 givenname: Isabella surname: Sinelli fullname: Sinelli, Isabella – sequence: 66 givenname: Palak surname: Singh fullname: Singh, Palak – sequence: 67 givenname: Andrew surname: Snyder fullname: Snyder, Andrew – sequence: 68 givenname: Maxwell T surname: Stauffer fullname: Stauffer, Maxwell T – sequence: 69 givenname: Jennifer surname: Thompson fullname: Thompson, Jennifer – sequence: 70 givenname: Christopher J surname: Tignanelli fullname: Tignanelli, Christopher J – sequence: 71 givenname: Tannon L surname: Tople fullname: Tople, Tannon L – sequence: 72 givenname: Walker J surname: Tordsen fullname: Tordsen, Walker J – sequence: 73 givenname: Ray Hb surname: Watson fullname: Watson, Ray Hb – sequence: 74 givenname: Beiqing surname: Wu fullname: Wu, Beiqing – sequence: 75 givenname: Adnin surname: Zaman fullname: Zaman, Adnin – sequence: 76 givenname: Madeline R surname: Zolik fullname: Zolik, Madeline R – sequence: 77 givenname: Lena surname: Zinkl fullname: Zinkl, Lena |
| Copyright | 2023 Elsevier Ltd Copyright © 2023 Elsevier Ltd. All rights reserved. 2023. Elsevier Ltd |
| Copyright_xml | – notice: 2023 Elsevier Ltd – notice: Copyright © 2023 Elsevier Ltd. All rights reserved. – notice: 2023. Elsevier Ltd |
| CorporateAuthor | the COVID-OUT Study Team COVID-OUT Study Team |
| CorporateAuthor_xml | – name: the COVID-OUT Study Team – name: COVID-OUT Study Team |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TZ 3V. 7QL 7RV 7U9 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR C1K CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P M7N NAPCQ PQEST PQQKQ PQUKI 7X8 |
| DOI | 10.1016/S1473-3099(23)00299-2 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Pharma and Biotech Premium PRO ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central AUTh Library subscriptions: ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Pharma and Biotech Premium PRO Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Pharma Collection Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Pharma and Biotech Premium PRO MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1474-4457 |
| EndPage | 1129 |
| ExternalDocumentID | 10_1016_S1473_3099_23_00299_2 37302406 S1473309923002992 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GrantInformation | Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences. |
| GrantInformation_xml | – fundername: Bill & Melinda Gates Foundation grantid: INV-017069 – fundername: NCATS NIH HHS grantid: UM1 TR004406 – fundername: NCATS NIH HHS grantid: UL1 TR002489 – fundername: NLM NIH HHS grantid: R01 LM012982 – fundername: NHLBI NIH HHS grantid: K23 HL133604 – fundername: NIDDK NIH HHS grantid: K23 DK124654 – fundername: NCATS NIH HHS grantid: UL1 TR002494 – fundername: NCI NIH HHS grantid: P01 CA254849 – fundername: NCATS NIH HHS grantid: KL2 TR002492 – fundername: NHLBI NIH HHS grantid: T32 HL129956 |
| GroupedDBID | --- --K --M -RU ..I .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 3V. 4.4 457 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAAJQ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAQFI AAQQT AAQXK AARKO AAWTL AAXUO AAYOK ABBQC ABJNI ABLVK ABMAC ABMZM ABUWG ABYKQ ACGFS ACPRK ACRLP ADBBV ADMUD AEKER AENEX AEVXI AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGEKW AGHFR AHMBA AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CJTIS CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HF~ HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OD- OO. OZT P-8 P-9 P2P PQQKQ PROAC PSQYO R2- RIG ROL RPZ SDF SDG SEL SES SPCBC SSH SSI SSZ T5K TLN UKHRP UV1 WOW XBR Z5R ZA5 AAMRU AAXKI AFCTW AKRWK ALIPV CGR CUY CVF ECM EIF NPM AAYXX CITATION 0TZ 7QL 7U9 7XB 8FK C1K H94 K9. M7N PQEST PQUKI 7X8 |
| ID | FETCH-LOGICAL-c440t-20426323f44a6bea6f6e7c61199559e5080ad4058377954aaee38ae89dddfe703 |
| ISSN | 1473-3099 1474-4457 |
| IngestDate | Sat Oct 26 03:55:03 EDT 2024 Thu Nov 07 07:33:05 EST 2024 Thu Sep 26 19:20:46 EDT 2024 Sat Nov 02 12:28:08 EDT 2024 Fri Feb 23 02:37:58 EST 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | Copyright © 2023 Elsevier Ltd. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c440t-20426323f44a6bea6f6e7c61199559e5080ad4058377954aaee38ae89dddfe703 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://cdr.lib.unc.edu/downloads/mg74qx797 |
| PMID | 37302406 |
| PQID | 2869561175 |
| PQPubID | 44001 |
| PageCount | 11 |
| ParticipantIDs | proquest_miscellaneous_2825159277 proquest_journals_2869561175 crossref_primary_10_1016_S1473_3099_23_00299_2 pubmed_primary_37302406 elsevier_sciencedirect_doi_10_1016_S1473_3099_23_00299_2 |
| PublicationCentury | 2000 |
| PublicationDate | October 2023 2023-10-00 20231001 |
| PublicationDateYYYYMMDD | 2023-10-01 |
| PublicationDate_xml | – month: 10 year: 2023 text: October 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: London |
| PublicationTitle | The Lancet infectious diseases |
| PublicationTitleAlternate | Lancet Infect Dis |
| PublicationYear | 2023 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Eurich, Weir, Majumdar (bib34) 2013; 6 Manson, Cook, Lee (bib14) 2019; 380 Castle, Dock, Hemmat (bib25) 2020 Sun, Liu, Xie, Yang, Zhao, Yang (bib30) 2021; 21 Salpeter, Greyber, Pasternak, Salpeter (bib33) 2010; 2010 Davis, Assaf, McCorkell (bib23) 2021; 38 (bib1) 2022 Kalafat, Sukur, Abdi, Thilaganathan, Khalil (bib9) 2018; 52 Parker, Weir (bib13) 2020; 17 Schaller, Sharma, Dupee (bib29) 2021; 6 Holmes, Brown, Hilaire, Wright (bib11) 2012; 12 Gates (bib39) 2020; 21 Sun, Liu, Huang (bib31) 2022; 29 Molloy, White, Nunn, Hayes, Wang, Harrison (bib12) 2022; 113 Bramante, Huling, Tignanelli (bib6) 2022; 387 Greenland, Mansournia, Altman (bib17) 2016; 352 Chang, Umpierrez, Inzucchi (bib37) 2022; 387 Zhao (bib10) 2015; 43 (bib4) 2022 Pocock, Stone (bib18) 2016; 375 Ventura-López, Cervantes-Luevano, Aguirre-Sánchez (bib22) 2022; 152 Chen, Han, Yang (bib32) Mantovani, Morrone, Patrono (bib24) 2022; 29 Pfaff, Girvin, Bennett (bib5) 2022; 4 Warnakulasuriya, Fernando, Adikaram (bib36) 2018; 14 Soriano, Murthy, Marshall, Relan, Diaz (bib20) 2022; 22 Karam, Morris, Bramante (bib26) 2021; 93 Villar, Soto Conti, Gunier (bib8) 2023; 401 Gordon, Jang, Bouhaddou (bib27) 2020; 583 Manson, Cook, Lee (bib15) 2019; 380 Reitz, Marroquin, Zenati (bib38) 2020; 155 Yang, Zhao, Tebbutt (bib2) 2022; 10 Cutler (bib3) 2022; 3 (bib19) Nov 11, 2021 Jorgensen, Miljanic, Tabbara (bib7) 2022; 4 Clegg, Jing, Penland (bib35) 2021; 23 Reis, Dos Santos Moreira-Silva, Silva (bib21) 2022; 10 Parthasarathy, Tandel, Siddiqui, Harshan (bib28) 2022; 323 Declercq, Van Damme, De Leeuw (bib16) 2021; 9 37666258 - Lancet Infect Dis. 2023 Oct;23(10):e400. doi: 10.1016/S1473-3099(23)00562-5 37302405 - Lancet Infect Dis. 2023 Oct;23(10):1096-1097. doi: 10.1016/S1473-3099(23)00355-9 Pfaff (10.1016/S1473-3099(23)00299-2_bib5) 2022; 4 Karam (10.1016/S1473-3099(23)00299-2_bib26) 2021; 93 Parker (10.1016/S1473-3099(23)00299-2_bib13) 2020; 17 Reitz (10.1016/S1473-3099(23)00299-2_bib38) 2020; 155 Gordon (10.1016/S1473-3099(23)00299-2_bib27) 2020; 583 Greenland (10.1016/S1473-3099(23)00299-2_bib17) 2016; 352 Schaller (10.1016/S1473-3099(23)00299-2_bib29) 2021; 6 Jorgensen (10.1016/S1473-3099(23)00299-2_bib7) 2022; 4 Kalafat (10.1016/S1473-3099(23)00299-2_bib9) 2018; 52 Parthasarathy (10.1016/S1473-3099(23)00299-2_bib28) 2022; 323 Salpeter (10.1016/S1473-3099(23)00299-2_bib33) 2010; 2010 Soriano (10.1016/S1473-3099(23)00299-2_bib20) 2022; 22 Cutler (10.1016/S1473-3099(23)00299-2_bib3) 2022; 3 Pocock (10.1016/S1473-3099(23)00299-2_bib18) 2016; 375 Gates (10.1016/S1473-3099(23)00299-2_bib39) 2020; 21 Holmes (10.1016/S1473-3099(23)00299-2_bib11) 2012; 12 Manson (10.1016/S1473-3099(23)00299-2_bib14) 2019; 380 Yang (10.1016/S1473-3099(23)00299-2_bib2) 2022; 10 Sun (10.1016/S1473-3099(23)00299-2_bib31) 2022; 29 Villar (10.1016/S1473-3099(23)00299-2_bib8) 2023; 401 Eurich (10.1016/S1473-3099(23)00299-2_bib34) 2013; 6 Davis (10.1016/S1473-3099(23)00299-2_bib23) 2021; 38 Sun (10.1016/S1473-3099(23)00299-2_bib30) 2021; 21 Chang (10.1016/S1473-3099(23)00299-2_bib37) 2022; 387 Bramante (10.1016/S1473-3099(23)00299-2_bib6) 2022; 387 Ventura-López (10.1016/S1473-3099(23)00299-2_bib22) 2022; 152 Chen (10.1016/S1473-3099(23)00299-2_bib32) Mantovani (10.1016/S1473-3099(23)00299-2_bib24) 2022; 29 Clegg (10.1016/S1473-3099(23)00299-2_bib35) 2021; 23 Manson (10.1016/S1473-3099(23)00299-2_bib15) 2019; 380 Warnakulasuriya (10.1016/S1473-3099(23)00299-2_bib36) 2018; 14 Zhao (10.1016/S1473-3099(23)00299-2_bib10) 2015; 43 Reis (10.1016/S1473-3099(23)00299-2_bib21) 2022; 10 Molloy (10.1016/S1473-3099(23)00299-2_bib12) 2022; 113 Castle (10.1016/S1473-3099(23)00299-2_bib25) 2020 Declercq (10.1016/S1473-3099(23)00299-2_bib16) 2021; 9 |
| References_xml | – volume: 152 year: 2022 ident: bib22 article-title: Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in vitro model and randomized, double-blind, phase IIb clinical trial publication-title: Biomed Pharmacother contributor: fullname: Aguirre-Sánchez – volume: 352 year: 2016 ident: bib17 article-title: Sparse data bias: a problem hiding in plain sight publication-title: BMJ contributor: fullname: Altman – volume: 93 start-page: 1843 year: 2021 end-page: 1846 ident: bib26 article-title: mTOR inhibition in COVID-19: a commentary and review of efficacy in RNA viruses publication-title: J Med Virol contributor: fullname: Bramante – volume: 43 start-page: 209 year: 2015 end-page: 216 ident: bib10 article-title: Mass weighted urn design—a new randomization algorithm for unequal allocations publication-title: Contemp Clin Trials contributor: fullname: Zhao – volume: 12 start-page: 127 year: 2012 ident: bib11 article-title: Healthcare provider attitudes towards the problem list in an electronic health record: a mixed-methods qualitative study publication-title: BMC Med Inform Decis Mak contributor: fullname: Wright – year: 2022 ident: bib1 article-title: Post-COVID conditions: information for healthcare providers – volume: 14 start-page: 553 year: 2018 end-page: 565 ident: bib36 article-title: Metformin in the management of childhood obesity: a randomized control trial publication-title: Child Obes contributor: fullname: Adikaram – volume: 323 year: 2022 ident: bib28 article-title: Metformin suppresses SARS-CoV-2 in cell culture publication-title: Virus Res contributor: fullname: Harshan – volume: 387 start-page: 1040 year: 2022 end-page: 1042 ident: bib37 article-title: Management of hyperglycemia in hospitalized, non-critically ill adults publication-title: N Engl J Med contributor: fullname: Inzucchi – volume: 380 start-page: 33 year: 2019 end-page: 44 ident: bib14 article-title: Vitamin D supplements and prevention of cancer and cardiovascular disease publication-title: N Engl J Med contributor: fullname: Lee – volume: 3 year: 2022 ident: bib3 article-title: The costs of long COVID publication-title: JAMA Health Forum contributor: fullname: Cutler – volume: 155 year: 2020 ident: bib38 article-title: Association between preoperative metformin exposure and postoperative outcomes in adults with type 2 diabetes publication-title: JAMA Surg contributor: fullname: Zenati – volume: 52 start-page: 706 year: 2018 end-page: 714 ident: bib9 article-title: Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials publication-title: Ultrasound Obstet Gynecol contributor: fullname: Khalil – volume: 29 start-page: 1240 year: 2022 end-page: 1254 ident: bib31 article-title: SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1 publication-title: Cell Death Differ contributor: fullname: Huang – volume: 4 start-page: e532 year: 2022 end-page: e541 ident: bib5 article-title: Identifying who has long COVID in the USA: a machine learning approach using N3C data publication-title: Lancet Digit Health contributor: fullname: Bennett – volume: 113 year: 2022 ident: bib12 article-title: Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: clear guidance is needed publication-title: Contemp Clin Trials contributor: fullname: Harrison – year: 2020 ident: bib25 article-title: Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets publication-title: bioRxiv contributor: fullname: Hemmat – volume: 6 year: 2021 ident: bib29 article-title: Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses publication-title: JCI Insight contributor: fullname: Dupee – ident: bib32 article-title: SARS-CoV-2 infection causes dopaminergic neuron senescence. contributor: fullname: Yang – volume: 21 start-page: e118 year: 2020 ident: bib39 article-title: Statistical significance and clinical evidence publication-title: Lancet Oncol contributor: fullname: Gates – volume: 6 start-page: 395 year: 2013 end-page: 402 ident: bib34 article-title: Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients publication-title: Circ Heart Fail contributor: fullname: Majumdar – volume: 10 start-page: e42 year: 2022 end-page: e51 ident: bib21 article-title: Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial publication-title: Lancet Glob Health contributor: fullname: Silva – volume: 17 start-page: 562 year: 2020 end-page: 566 ident: bib13 article-title: Non-adjustment for multiple testing in multi-arm trials of distinct treatments: rationale and justification publication-title: Clin Trials contributor: fullname: Weir – volume: 9 start-page: 1427 year: 2021 end-page: 1438 ident: bib16 article-title: Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial publication-title: Lancet Respir Med contributor: fullname: De Leeuw – volume: 401 start-page: 447 year: 2023 end-page: 457 ident: bib8 article-title: Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study publication-title: Lancet contributor: fullname: Gunier – volume: 38 year: 2021 ident: bib23 article-title: Characterizing long COVID in an international cohort: 7 months of symptoms and their impact publication-title: EClinicalMedicine contributor: fullname: McCorkell – volume: 380 start-page: 23 year: 2019 end-page: 32 ident: bib15 article-title: Marine n-3 fatty acids and prevention of cardiovascular disease and cancer publication-title: N Engl J Med contributor: fullname: Lee – year: 2022 ident: bib4 article-title: Long COVID – volume: 22 start-page: e102 year: 2022 end-page: e107 ident: bib20 article-title: A clinical case definition of post-COVID-19 condition by a Delphi consensus publication-title: Lancet Infect Dis contributor: fullname: Diaz – year: Nov 11, 2021 ident: bib19 article-title: COVID-19 rapid guideline: managing the long-term effects of COVID-19 – volume: 21 start-page: 578 year: 2021 ident: bib30 article-title: Metformin attenuates diabetic renal injury via the AMPK-autophagy axis publication-title: Exp Ther Med contributor: fullname: Yang – volume: 2010 year: 2010 ident: bib33 article-title: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus publication-title: Cochrane Database Syst Rev contributor: fullname: Salpeter – volume: 375 start-page: 861 year: 2016 end-page: 870 ident: bib18 article-title: The primary outcome fails—what next? publication-title: N Engl J Med contributor: fullname: Stone – volume: 23 start-page: 1101 year: 2021 end-page: 1110 ident: bib35 article-title: Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials publication-title: Diabetes Obes Metab contributor: fullname: Penland – volume: 583 start-page: 459 year: 2020 end-page: 468 ident: bib27 article-title: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing publication-title: Nature contributor: fullname: Bouhaddou – volume: 10 start-page: e81 year: 2022 ident: bib2 article-title: A glimpse into long COVID and symptoms publication-title: Lancet Respir Med contributor: fullname: Tebbutt – volume: 387 start-page: 599 year: 2022 end-page: 610 ident: bib6 article-title: Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19 publication-title: N Engl J Med contributor: fullname: Tignanelli – volume: 4 year: 2022 ident: bib7 article-title: Inclusion of pregnant and breastfeeding women in nonobstetrical randomized controlled trials publication-title: Am J Obstet Gynecol MFM contributor: fullname: Tabbara – volume: 29 start-page: 1891 year: 2022 end-page: 1900 ident: bib24 article-title: Long COVID: where we stand and challenges ahead publication-title: Cell Death Differ contributor: fullname: Patrono – volume: 10 start-page: e81 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib2 article-title: A glimpse into long COVID and symptoms publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(22)00217-X contributor: fullname: Yang – volume: 9 start-page: 1427 year: 2021 ident: 10.1016/S1473-3099(23)00299-2_bib16 article-title: Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00377-5 contributor: fullname: Declercq – volume: 93 start-page: 1843 year: 2021 ident: 10.1016/S1473-3099(23)00299-2_bib26 article-title: mTOR inhibition in COVID-19: a commentary and review of efficacy in RNA viruses publication-title: J Med Virol doi: 10.1002/jmv.26728 contributor: fullname: Karam – volume: 38 year: 2021 ident: 10.1016/S1473-3099(23)00299-2_bib23 article-title: Characterizing long COVID in an international cohort: 7 months of symptoms and their impact publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2021.101019 contributor: fullname: Davis – volume: 401 start-page: 447 year: 2023 ident: 10.1016/S1473-3099(23)00299-2_bib8 article-title: Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study publication-title: Lancet doi: 10.1016/S0140-6736(22)02467-9 contributor: fullname: Villar – volume: 10 start-page: e42 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib21 article-title: Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial publication-title: Lancet Glob Health doi: 10.1016/S2214-109X(21)00448-4 contributor: fullname: Reis – volume: 21 start-page: e118 year: 2020 ident: 10.1016/S1473-3099(23)00299-2_bib39 article-title: Statistical significance and clinical evidence publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30854-X contributor: fullname: Gates – volume: 152 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib22 article-title: Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in vitro model and randomized, double-blind, phase IIb clinical trial publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2022.113223 contributor: fullname: Ventura-López – volume: 387 start-page: 599 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib6 article-title: Randomized trial of metformin, ivermectin, and fluvoxamine for COVID-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2201662 contributor: fullname: Bramante – volume: 6 year: 2021 ident: 10.1016/S1473-3099(23)00299-2_bib29 article-title: Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses publication-title: JCI Insight doi: 10.1172/jci.insight.148003 contributor: fullname: Schaller – volume: 4 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib7 article-title: Inclusion of pregnant and breastfeeding women in nonobstetrical randomized controlled trials publication-title: Am J Obstet Gynecol MFM doi: 10.1016/j.ajogmf.2022.100700 contributor: fullname: Jorgensen – volume: 52 start-page: 706 year: 2018 ident: 10.1016/S1473-3099(23)00299-2_bib9 article-title: Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials publication-title: Ultrasound Obstet Gynecol doi: 10.1002/uog.19084 contributor: fullname: Kalafat – volume: 23 start-page: 1101 year: 2021 ident: 10.1016/S1473-3099(23)00299-2_bib35 article-title: Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials publication-title: Diabetes Obes Metab doi: 10.1111/dom.14313 contributor: fullname: Clegg – volume: 22 start-page: e102 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib20 article-title: A clinical case definition of post-COVID-19 condition by a Delphi consensus publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00703-9 contributor: fullname: Soriano – volume: 323 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib28 article-title: Metformin suppresses SARS-CoV-2 in cell culture publication-title: Virus Res contributor: fullname: Parthasarathy – volume: 2010 year: 2010 ident: 10.1016/S1473-3099(23)00299-2_bib33 article-title: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus publication-title: Cochrane Database Syst Rev doi: 10.1002/14651858.CD002967.pub3 contributor: fullname: Salpeter – volume: 29 start-page: 1240 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib31 article-title: SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1 publication-title: Cell Death Differ doi: 10.1038/s41418-021-00916-7 contributor: fullname: Sun – volume: 43 start-page: 209 year: 2015 ident: 10.1016/S1473-3099(23)00299-2_bib10 article-title: Mass weighted urn design—a new randomization algorithm for unequal allocations publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2015.06.008 contributor: fullname: Zhao – volume: 3 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib3 article-title: The costs of long COVID publication-title: JAMA Health Forum doi: 10.1001/jamahealthforum.2022.1809 contributor: fullname: Cutler – volume: 21 start-page: 578 year: 2021 ident: 10.1016/S1473-3099(23)00299-2_bib30 article-title: Metformin attenuates diabetic renal injury via the AMPK-autophagy axis publication-title: Exp Ther Med doi: 10.3892/etm.2021.10010 contributor: fullname: Sun – year: 2020 ident: 10.1016/S1473-3099(23)00299-2_bib25 article-title: Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets publication-title: bioRxiv contributor: fullname: Castle – volume: 155 year: 2020 ident: 10.1016/S1473-3099(23)00299-2_bib38 article-title: Association between preoperative metformin exposure and postoperative outcomes in adults with type 2 diabetes publication-title: JAMA Surg doi: 10.1001/jamasurg.2020.0416 contributor: fullname: Reitz – volume: 380 start-page: 23 year: 2019 ident: 10.1016/S1473-3099(23)00299-2_bib15 article-title: Marine n-3 fatty acids and prevention of cardiovascular disease and cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1811403 contributor: fullname: Manson – volume: 583 start-page: 459 year: 2020 ident: 10.1016/S1473-3099(23)00299-2_bib27 article-title: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing publication-title: Nature doi: 10.1038/s41586-020-2286-9 contributor: fullname: Gordon – volume: 380 start-page: 33 year: 2019 ident: 10.1016/S1473-3099(23)00299-2_bib14 article-title: Vitamin D supplements and prevention of cancer and cardiovascular disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1809944 contributor: fullname: Manson – volume: 113 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib12 article-title: Multiplicity adjustments in parallel-group multi-arm trials sharing a control group: clear guidance is needed publication-title: Contemp Clin Trials doi: 10.1016/j.cct.2021.106656 contributor: fullname: Molloy – ident: 10.1016/S1473-3099(23)00299-2_bib32 contributor: fullname: Chen – volume: 4 start-page: e532 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib5 article-title: Identifying who has long COVID in the USA: a machine learning approach using N3C data publication-title: Lancet Digit Health doi: 10.1016/S2589-7500(22)00048-6 contributor: fullname: Pfaff – volume: 387 start-page: 1040 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib37 article-title: Management of hyperglycemia in hospitalized, non-critically ill adults publication-title: N Engl J Med doi: 10.1056/NEJMclde2204691 contributor: fullname: Chang – volume: 17 start-page: 562 year: 2020 ident: 10.1016/S1473-3099(23)00299-2_bib13 article-title: Non-adjustment for multiple testing in multi-arm trials of distinct treatments: rationale and justification publication-title: Clin Trials doi: 10.1177/1740774520941419 contributor: fullname: Parker – volume: 375 start-page: 861 year: 2016 ident: 10.1016/S1473-3099(23)00299-2_bib18 article-title: The primary outcome fails—what next? publication-title: N Engl J Med doi: 10.1056/NEJMra1510064 contributor: fullname: Pocock – volume: 14 start-page: 553 year: 2018 ident: 10.1016/S1473-3099(23)00299-2_bib36 article-title: Metformin in the management of childhood obesity: a randomized control trial publication-title: Child Obes doi: 10.1089/chi.2018.0043 contributor: fullname: Warnakulasuriya – volume: 6 start-page: 395 year: 2013 ident: 10.1016/S1473-3099(23)00299-2_bib34 article-title: Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients publication-title: Circ Heart Fail doi: 10.1161/CIRCHEARTFAILURE.112.000162 contributor: fullname: Eurich – volume: 12 start-page: 127 year: 2012 ident: 10.1016/S1473-3099(23)00299-2_bib11 article-title: Healthcare provider attitudes towards the problem list in an electronic health record: a mixed-methods qualitative study publication-title: BMC Med Inform Decis Mak doi: 10.1186/1472-6947-12-127 contributor: fullname: Holmes – volume: 352 year: 2016 ident: 10.1016/S1473-3099(23)00299-2_bib17 article-title: Sparse data bias: a problem hiding in plain sight publication-title: BMJ contributor: fullname: Greenland – volume: 29 start-page: 1891 year: 2022 ident: 10.1016/S1473-3099(23)00299-2_bib24 article-title: Long COVID: where we stand and challenges ahead publication-title: Cell Death Differ contributor: fullname: Mantovani |
| SSID | ssj0017104 |
| Score | 2.6970007 |
| Snippet | Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether... Summary Background Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1119 |
| SubjectTerms | Adult Antigens Breastfeeding & lactation Clinical trials Consent COVID-19 COVID-19 Drug Treatment Diabetes mellitus Diagnosis Double-Blind Method Drug dosages Drug stores Electronic health records Female Fluvoxamine Health services Humans Incidence Infections Infectious diseases Ivermectin Ivermectin - therapeutic use Kidney diseases Male Metformin Metformin - therapeutic use Middle Aged Oral administration Outpatients Placebos Post-Acute COVID-19 Syndrome Pregnancy Prevention Public health Rain water Randomization SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Signs and symptoms Subgroups Treatment Outcome Viral diseases Web portals Womens health |
| Title | Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial |
| URI | https://dx.doi.org/10.1016/S1473-3099(23)00299-2 https://www.ncbi.nlm.nih.gov/pubmed/37302406 https://www.proquest.com/docview/2869561175 https://www.proquest.com/docview/2825159277 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3raxNBEF_aCiKIaH1Fq6yg0JJcvdt7-01tpH7QgE1F_HJsbvdoMCY1yQn-Vf6LzuzzIhYf4Jcj2d3cI_O73ZnZ38wQ8rgQdVTyLArYRKK3Kq2DshQwGYoGzOc4Z6JG18DxSf72Q3E0TIZb27Y8mG_7r5KGNpA1Rs7-hbTdSaEBPoPM4QhSh-MfyX3Urk2u1A6JHDkXo_evj4KoNOmWal1MVBGeF6t14LrBPhZTrUbCs_ejsA-3vj5Tzlk9aHQ6fsJKHSWt-IiK4Kkco7DwiQUgR3tQv7RcLNvzmQwmoMyqJsw0PpvJWaCiSVTLGayj_bivyod0VWUEsI7QdoyxdmU3lLxzf8k_IzgceeXb3PO-X7QrafnGnfLSU5hjv05VIVvN6fcuYXgxPs1MjBuv0V9h-oxjhHmKnfHW2YgdT4_CCT7J4yAOdVGmQ2nbkiBJdKJsuyroKGiL_rAzx8PqUHb0BVRYf7kWabfIibsiiAmzZJS4EVqamM_NVN9qLA4FuxAHgWpxicEEilTVj-k7tzsGWqFiS9gz-8i0p_5y-yw-MJe6SOe6yKZSutX4OrlmjCL6XKP5BtmS811y-Y2hfeySq9q5THXM3E3y3YOcOpDTRUMtiingkDqQY88GyKkDOUWQ0yikGuR030H84BnltAPvAfXgHtCfoD2gm8CG7whrGlMF61vk9NVw_PI4MJVHgjpJwjVMKKqOQdwkCc8mkmdNJvM6izCfQVpKMGpCLsDUKTBdZ5pwLmVccFmUQohGwiJ6m-zMF3N5l9AiaqJUMNDzGeZtauAMBQe7h_GmkEXKe-TQyqY61wlmKse8RGFWKMyKxZUSZsV6pLASrIyWrLXfCoD3u5_uWYlXZspaVazIMLgdzIgeeeS64d_EnUM-l_BuVyrAPS1ZnvfIHY0Ud7Mx6AhoFtz79_u6T674F3iP7KyXrXxAtleifaiA_wN6evI2 |
| link.rule.ids | 315,782,786,27935,27936 |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Outpatient+treatment+of+COVID-19+and+incidence+of+post-COVID-19+condition+over+10+months+%28COVID-OUT%29%3A+a+multicentre%2C+randomised%2C+quadruple-blind%2C+parallel-group%2C+phase+3+trial&rft.jtitle=The+Lancet+infectious+diseases&rft.au=Bramante%2C+Carolyn+T&rft.au=Buse%2C+John+B&rft.au=Liebovitz%2C+David+M&rft.au=Nicklas%2C+Jacinda+M&rft.date=2023-10-01&rft.pub=Elsevier+Ltd&rft.issn=1473-3099&rft.eissn=1474-4457&rft.volume=23&rft.issue=10&rft.spage=1119&rft.epage=1129&rft_id=info:doi/10.1016%2FS1473-3099%2823%2900299-2&rft.externalDocID=S1473309923002992 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1473-3099&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1473-3099&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1473-3099&client=summon |